)
Edge14 Aug 2026
Deutsche Qualität: The Story of Birkenstock
From an 18th-century German shoemaker to a global footwear brand, how Birkenstock turned an orthopedic insole into the world's most popular sandal.
Cue Biopharma
Cue Biopharma (CUE) investor relations material
Cue Biopharma Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary14 Aug, 2026
Executive summary
Entered exclusive license agreement with Ascendant Health Sciences for CUE-221, a novel anti-IgE antibody, with a $15M upfront payment and up to $676.5M in milestones and royalties.
Completed a $27.6M private placement in May 2026 and a $49.8M private placement in July 2026 to strengthen liquidity.
Appointed a new President and CEO, Shao-Lee Lin, with a new executive employment agreement.
Financial highlights
Collaboration revenue for Q2 2026 was $7.9M, up from $3.0M in Q2 2025, driven by BI milestone payments.
Net loss for Q2 2026 was $153.1M, compared to $8.5M in Q2 2025, primarily due to one-time non-cash charges related to warrant issuances and the Ascendant license.
Cash and cash equivalents as of June 30, 2026, were $17.4M, with an additional $49.8M received in July 2026.
Outlook and guidance
Cash runway expected to last at least twelve months from the financial statement issuance date, supported by recent financings.
Plans to initiate a global Phase 2b trial for CUE-221 in food allergy after reviewing Phase 2 data from China.
IND submission for CUE-401 expected by end of 2026, with Phase 1 trial initiation planned.
CUE-221 manufacturing rights amendment for China
Valuation of the Ascendant Top-Up Share liability
Explain the $90M warrant issuance loss
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Cue Biopharma
- Advancing novel therapies for allergy and autoimmunity with key milestones expected in 2026.CUE
Corporate presentation - Registering 1.5M shares for resale post-$50M private placement; no proceeds to company.CUERegistration filing
- CUE-401 shows durable Treg induction and disease suppression, advancing toward clinical development.CUEStatus Update
- 551,724 shares registered for resale by a licensing partner; company receives no offering proceeds.CUERegistration filing
- All proposals, including share issuance and the 2026 Stock Plan, were approved by stockholders.CUEEGM 2026
- Registering 4.1M shares for resale after $30M private placement; proceeds only from warrant exercises.CUERegistration filing
- Advancing dual-mechanism immunotherapies with major clinical milestones expected by end of 2026.CUEJefferies Global Healthcare Conference 2026
- Approval sought for share issuance, new incentive plan, and meeting adjournment authority.CUEProxy filing
- Cash burn reduced, revenue up, and clinical progress continues amid need for new capital.CUEQ2 2024
Next Cue Biopharma earnings date
Q3 202611 Nov, 2026
Cue Biopharma
Next Cue Biopharma earnings date
Q3 202611 Nov, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage